文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

脑转移介入性临床试验的现状与展望:基于ClinicalTrials.gov的分析

Current status and perspectives of interventional clinical trials for brain metastases: analysis of ClinicalTrials.gov.
PubMed 文献 · Radiat Oncol · 2023-04-04

该研究利用ClinicalTrials.gov注册库,分析了正在进行的评估全身治疗、放疗和手术单独或联合用于脑转移患者的II期和III期临床试验。共筛选出168项试验(133项II期、35项III期),其中163项使用全身治疗,96项包含放疗(54项为单纯放疗,42项联合全身治疗)。结论认为,全身靶向和/或免疫治疗联合或不联合放疗在脑转移常规治疗中的应用日益增多,立体定向放射外科正逐步取代全脑放疗。

要点

  • 共分析168项脑转移临床试验,其中133项为II期、35项为III期。
  • 163项试验使用全身治疗,113项使用酪氨酸激酶抑制剂,50项使用单克隆抗体。
  • 96项试验包含放疗,其中54项为单纯放疗,42项联合全身治疗。

核心结论

  • 全身靶向和/或免疫治疗联合或不联合放疗在脑转移常规治疗中的应用日益增多。
  • 立体定向放射外科正逐步取代全脑放疗。
  • 这些试验旨在解决脑转移患者管理的多个问题,包括不同癌症组织学类型的推荐 upfront 治疗以及全身治疗与放疗之间的最佳时机对脑控制和神经认知结局及生活质量的影响。

研究设计与样本

  • 利用ClinicalTrials.gov注册库(超过40万项注册试验)进行分析。
  • 筛选并分析了正在进行的评估不同全身治疗、放疗和手术单独或联合用于脑转移患者的II期和III期临床试验。

主要发现

  • 共纳入168项试验,其中133项为II期,35项为III期。
  • 大多数试验主要针对肺癌、乳腺癌和黑色素瘤脑转移患者的治愈性治疗。
  • 163项试验使用全身治疗;其中113项使用酪氨酸激酶抑制剂(较常见为奥希替尼、埃克替尼和吡咯替尼),50项使用单克隆抗体(较常见为曲妥珠单抗、帕博利珠单抗、纳武利尤单抗),20项使用传统化疗,6项未使用肿瘤活性药物。
  • 96项试验包含放疗;其中54项为单纯放疗,42项为放疗联合全身治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of brain metastases (BM), the major cause of cancer morbidity and mortality, is becoming an emerging area of interest. Surgery, whole brain radiation therapy (WBRT), or stereotactic radiosurgery (SRS), have historically been the main focal treatments for BM. However, the introduction of innovative targeted- and immune-based therapies is progressively changing the paradigm of BM treatment, resulting in an increase in clinical trials investigating new therapeutic strategies. METHODS: Using ClinicalTrials.gov, the largest clinical trial registry with over 400,000 registered trials, we performed an analysis of phase II and phase III ongoing trials evaluating different systemic therapies, radiotherapy (RT), and surgery given alone or in combination in patients with BM. RESULTS: One hundred sixty-eight trials, 133 phase II and 35 phase III; the largest part having primarily the curative treatment of patients with BM from lung cancer, breast cancer and melanoma, were selected. One hundred sixty-three trials used systemic therapies. One hundred thirteen used tyrosine kinase inhibitors, more frequently Osimertinib, Icotinib and Pyrotinib, 50 used monoclonal antibodies, more frequently Trastuzumab, Pembrolizumab, Nivolumab, 20 used conventional chemotherapies whilst no oncological active drugs were used in 6 trials. Ninety-six trials include RT; 54 as exclusive treatment and 42 in combination with systemic therapies. CONCLUSION: Systemic targeted- and/or immune-based therapies, combined or not with RT, are increasingly used in the routine of BM treatment. SRS is progressively replacing WBRT. All these trials intend to address multiple questions on the management of patients with BMs, including the recommended upfront treatment for different cancer histologies and the optimal timing between systemic therapies and radiation regarding brain control and neurocognitive outcome and quality of life.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Tini P, Marampon F, Giraffa M, et al. Current status and perspectives of interventional clinical trials for brain metastases: analysis of ClinicalTrials.gov. Radiat Oncol. 2023. PMID: 37016421. doi:10.1186/s13014-023-02243-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。